Not Yet Recruiting
PHASE2
INTERVENTIONAL
NCT07187856
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus
Interventions
Name:
PG-102
Type:
DRUG
Description:
PG-102 is administered subcutaneously once weekly with a titration regimen.
Name:
Placebo
Type:
DRUG
Description:
Placebo is administered subcutaneously once weekly.
Name:
Semaglutide
Type:
DRUG
Description:
Open-label semaglutide is administered subcutaneously once weekly with titration regimen.
Primary Outcomes
Measure:
Absolute change in HbA1c From Baseline at Week 24
TimeFrame:
24 weeks
Description:
Mean absolute change in glycated hemoglobin (HbA1c) from baseline to Week 24, comparing PG-102 with placebo.
Trial Information
NCT ID
NCT07187856
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
ProGen. Co., Ltd.
Last Updated
December 15, 2025